Palvella Therapeutics, Inc. Common Stock
Market Cap
1.5B
Short interest (May 15)
15.0%
Net Short (Jun 03 ): -0.8%
Borrow Fee
0.47%
↑ 0.1%
Available Shares
90K
↓ 3.2%
Price Chart
Company Overview
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.